
Anticoccidial Drugs Market
Get a free sample of this report
Form submitted successfully!
Error submitting form. Please try again.
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!

Request Sectional Data
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Anticoccidial Drugs Market size was valued at USD 183.1 million in 2023 and is anticipated to grow at a CAGR of 4.1% from 2024 and 2032. One of the key drivers is the increasing demand for poultry products, such as meat and eggs, due to the growing demand for protein-rich diets.

This has led to a higher incidence of coccidiosis in poultry, necessitating the use of anticoccidial drugs for prevention and treatment. Additionally, the intensification of poultry farming practices, aimed at meeting the rising demand, has created a conducive environment for the spread of coccidiosis, further fueling the demand for these drugs. Furthermore, growing awareness among farmers about the economic benefits of using anticoccidial drugs, such as improved feed conversion rates and reduced mortality rates, is also contributing to market growth.
Anticoccidial drugs are pharmaceutical agents used to prevent and treat coccidiosis, a parasitic disease caused by protozoa of the genus Eimeria. This protozoon infects the intestinal tracts of animals, poultry, cattle, sheep, goats, swine, and companion animals. Coccidiosis can cause significant economic losses in the livestock industry due to decreased productivity, weight loss, and mortality.
| Key Takeaway | Details |
|---|---|
| Market Size & Growth | |
| Base Year | 2023 |
| Market Size in 2023 | USD 183.1 Million |
| Forecast Period 2024 – 2032 CAGR | 4.1% |
| Market Size in 2032 | USD 262.3 Million |
| Key Market Trends | |
| Growth Drivers |
|
| Pitfalls & Challenges |
|

Based on drug class, the market is segmented into synthetic compounds and polyether antibiotics or ionophores. The synthetic compounds segment dominated the market in 2023 with a market share of 62.1%.
Based on drug action, the anticoccidial drugs market is classified into coccidiostatic and coccidiocidal. The coccidiostatic segment dominated the global market and is anticipated to showcase growth at a CAGR 3.9% between 2024 – 2032.

Based on animal type, the anticoccidial drugs market is divided into companion animals and livestock animals. The companion animals segment held highest market share and was valued at USD 104.7 million in 2023. The companion animals’ segment is further segmented into dogs, cats, and other companion animals.
Based on distribution channel, the anticoccidial drugs market is categorized into veterinary hospitals & pharmacies, retail pharmacies, and other distribution channels. The veterinary hospitals & pharmacies segment accounted for USD 83.7 million in 2023 and is expected to reach USD 118.8 million by 2032.

North America anticoccidial drugs market is projected to grow at a CAGR of 3.9% over the forecast period to reach USD 106.8 million by 2032.
The U.S. anticoccidial drugs market was valued at USD 70.3 million and is anticipated to experience growth at 3.8% CAGR over the coming years.
Germany anticoccidial drugs market is anticipated to witness lucrative growth in near future.
India anticoccidial drugs market is anticipated to showcase significant growth from 2024 - 2032.
The market is characterized by several key players are vying for market share through strategies such as product innovation, partnerships, mergers, and acquisitions. Companies such as Zoetis Inc., Elanco, Merck & Co. Inc., Bayer AG, and Ceva are among the prominent players driving innovation and market growth through the development of novel anticoccidial drugs.
Prominent players operating in the anticoccidial drugs industry include:
The anticoccidial drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:
The above information is provided for the following regions and countries:
Elanco Animal Health Incorporated, Huvepharma EOOD, Impextraco NV, Merck & Co., Inc, Phibro Animal Health Corporation, Vetoquinol SA, Virbac SA, and Zoetis Inc. among others.
North America anticoccidial drugs market is projected to witness 3.9% CAGR during 2024-2032, owing to substantial livestock and poultry industry, where coccidiosis is a prevalent concern.
The synthetic compounds segment of the anticoccidial drugs industry held 62.1% share in 2023 and will expand rapidly through 2032, due to its high efficacy and broad spectrum of activity against various coccidia species.
The global anticoccidial drugs market size was valued at USD 183.1 million in 2023 and is anticipated to grow at 4.1% CAGR during 2024-2032, driven by the increasing demand for poultry products, such as meat and eggs, due to the growing demand for protein-rich diets.
Related Reports
Buy Now


